Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2018 | FORTE: effective treatment of newly diagnosed MM with KRd

Francesca Gay • 14 Jun 2018
EHA 2018
Multiple Myeloma Carfilzomib Cyclophosphamide Dexamethasone Lenalidomide

The FORTE trial (NCT02203643) aimed to compare responses to carfilzomib when combined with lenalidomide-dexamethasone (KRd) or with cyclophosphamide-dexamethasone (KCd) for newly diagnosed multiple myeloma (MM). Francesca Gay, MD, from the Azienda Ospedaliera Città della Salute e della Scienza di Torino, Turin, Italy, discusses the results presented from this study at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden. While both therapies were effective and well tolerated, KRd treatment yielded better overall responses, in addition to improved rates of MRD negativity, in both high- and low-risk patients.

More from Francesca Gay

1:46
FORTE: MRD by MFC or NGS in myeloma
Francesca Gay • 14 Dec 2020
1:30
MRD: Paving the way for future clinical trials in myeloma
Francesca Gay • 14 Dec 2020
0:45
FORTE: KRd versus KCd treatment for myeloma
Francesca Gay • 14 Dec 2020
1:06
MRD evaluation by MFC and NGS for MM
Francesca Gay • 7 Dec 2019

Related Videos

3:54
Cilta-cel as a potential new SoC for R/R multiple myeloma: insights from the CARTITUDE-4 trial
Roberto Mina • 23 Apr 2024
1:41
CRS and neurotoxicity in bispecific antibody and CAR-T therapy for multiple myeloma
Eden Biltibo • 15 Apr 2024
0:36
The recent expanded FDA approval of cilta-cel and ide-cel into earlier lines of myeloma treatment
Sergio Giralt • 16 Apr 2024
1:48
Tackling underrepresentation of minorities in CAR-T clinical trials
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals